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It is often useful for the phy-
sician to classify diabetes as stable 
or unstable. Maturity-onset diabetes 
is usually stable, and its manage-
ment is not difficult, provided the 
patient is interested and cooperative. 
Tendency to obesity, relative in-
sensitivity to insulin, and absence 
of ketosis are characteristic of such 
patients. Relative insensitivity to in-
sulin does not imply unresponsive-
ness, but rather that the blood sugar 
is not overly labile and does not 
fall sharply in response to exercise 
or injected insulin. Many patients 
with such insensitivity to insulin are 
adequately managed on diet, alone 
or in combination with the oral hy-
poglycemic agents. When the latter 
fail , usually a single morning dose 
of long-acting insulin is satisfactory 
in controlling glycosuria and hy-
perglycemia during a 24-hour in-
terval. Occasionally a small dose of 
crystalline insulin given in the same 
injection will be needed to control 
glycosuria between breakfast and 
lunch. 
UNSTABLE DIABETES 
Unstable or "brittle" diabetes 
usually is associated with the 
growth-onset type, although it may 
be present in many patients whose 
diabetes appeared after the age of 
40. "Brittle" diabetics are insulin 
dependent and prone to ketosis. 
They are usually of average or be-
low average weight and often are 
emotionally labile. Marked fluctua-
tions in blood glucose following ex-
ercise or ingestion of food , as well 
as during infections, may lead to 
periods of marked hyperglycemia or 
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hypoglycemia. These rapid and of-
ten unpredictable shifts in blood 
glucose are disturbing to the pa-
tient and his family and frustrating 
to the physician. 
In considering the causes of un-
stable diabetes one must differen-
tiate between primary instability 
and transient conditions which may 
influence diabetes unfavorably and 
cause temporary instability. Stable 
diabetes may be aggravated by a 
number of conditions such as infec-
tion, thyrotoxicosis, and physical or 
emotional stress. If treatment is 
poorly planned or carried out, er-
ratic behavior of the blood glucose 
may result from giving excessively 
large doses of insulin, or from giv-
ing it at the wrong time of day. Re-
bound hyperglycemia and occa-
sionally ketosis may result from 
excessive insulin administration and 
may, in some instances, be re-
sponsible for periods of instability 
in an otherwise stable diabetic 
(Somogyi, 1960). 
Primary instability characterizes 
the "very brittle patient." The basic 
cause is complete or nearly com-
plete lack of endogenous insulin 
production. This condition usually 
manifests itself during the growth 
years ; after diabetes has been pres-
ent five years or more, little or no 
insulin can be found in the blood. 
Examination of pancreatic tissue 
from a patient with this type of di-
abetes reveals little or no insulin. 
This fact accounts for unrespon-
siveness to the sulfonylurea com-
pounds wl1ose major action de-
pends upon the ability of the 
pancreas to1 produce and release in-
sulin. 
The "brittle" diabetic is there-
fore totally dependent on exogenous 
insulin. Normal homeostatic mech-
anisms concerned with the release 
of pancreatic insulin in response to 
metabolic needs are no longer pres-
ent. The physician then faces a dif-
ficult task in attempting to supply 
insulin by injection, in an effort to 
prevent glycosuria and to maintain 
the blood glucose at a normal level 
throughout each 24-hour period. 
As Dr. Alexander Marble para-
phrased this problem, "One strives 
to mimic nature, and, of course, 
succeeds only imperfectly." 
MANAGEMENT OF PRIMARY 
INSTABILITY 
In the management of the un-
stable or "brittle" diabetic, those 
conditions which aggravate dia-
betes should be sought and treated. 
One should carefully avoid over-
dosage of insulin. This is extremely 
important since it is hypoglycemia, 
not diabetes itself, that most often 
incapacitates the diabetic in his 
job and in many other social situa-
tions. Management is based on an 
attempt to secure uniformity of the 
controllable factors which influence 
blood glucose. These include diet, 
insulin, and physical activity. The 
diet should be reasonably constant 
from day to day in conjunction 
with a relatively fixed , daily insulin 
dose. Physical activity lowers the 
requirement for injected insulin, 
and strenuous or unusual exercise 
may precipitate hypoglycemic epi-
sodes; in such circumstances addi-
tional food may be taken. If un-
usual physical activity is antici-
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pated, an appropriate decrease may 
be made in the dose of insulin. 
The "brittle" diabetic invariably 
requires daily injections of insulin. 
There are various insulin programs, 
most of which include giving the 
major portion of the day's insulin 
in the form of a long-acting insulin, 
either NPH or Lente insulin, as an 
"anchor" dose before breakfast. If 
one has been careful to keep uni-
form the patient's daily diet, ex-
ercise, and insulin dose, this single 
morning dose may be all that is 
needed to maintain blood glucose 
within the normal range during a 
24-hour period. Unfortunately, this 
is most often not the case in the 
unstable diabetic. Lack of uniform-
ity, either in diet or exercise, while 
receiving a relatively fixed dose of 
daily insulin accounts for many of 
the wide swings in blood glucose 
following insulin injection. 
In either stable or unstable dia-
betes, despite satisfactory control 
in the afternoon and evening fol-
lowing a single morning dose of 
long-acting insulin, the fasting 
blood sugar may be high the fol-
lowing morning. One may effec-
tively control this by a split dose 
of long-acting insulin, employing a 
smaller increment, usually 5 to 10 
units, at bedtime. If the tests at 
supper are poor, then giving this 
smaller increment before supper 
along with a small dose of regular 
insulin may bring about satisfac-
tory control. If either the single 
morning dose or split dose brings 
about satisfactory control before 
breakfast and supper, yet fails to 
control hyperglycemia and gly-
cosuria before lunch, then a small 
dose of crystalline insulin may be 
given along with the pre-breakfast 
injection of longer-acting insulin. 
Adjustments in insulin dosage 
are usually made in 3 to 5 unit 
increments, allowing two to three 
days between successive changes. 
Ordinarily, changes in insulin dose 
are not made frequently, and cer-
tainly not on the basis of a single 
test, but rather according to the 
general trend of tests at a given 
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time of day. The patient should 
keep a record of urine tests so the 
degree of control at any given time 
of day can be easily ascertained. 
Phenformin (DBI) has been 
recommended as an additional sup-
plement to insulin in "brittle" pa-
tients in an attempt to lessen fluct-
uations in the blood sugar. This 
was tried without much success in 
approximately 20 juvenile patients 
over a two-year period at the MCV 
diabetic clinic. The insulin dose was 
significantly decreased, yet these 
patients remained just as "brittle" 
while on phenformin (DBI). 
Causes of Primary Instability 
Although the basic cause of pri-
mary instability seems to be nearly 
total lack of endogenous insulin 
production, the factors contributing 
to the "brittle" state are poorly un-
derstood. The rebound phenome-
non following excessive insulin dos-
age (Somogyi, 1960) all too often 
is not corrected simply by reducing 
insulin dosage. In many instances 
this may result in an increasing fre-
quency of periods of ketosis. 
The capricious response of such 
patients to insulin therapy might 
arise from alterations in the han-
dling and disposal of insulin in the 
body. Prout and Katims (1959) 
advanced the hypothesis that some 
type of plasma binding of insulin 
with erratic release of free insulin 
might result in a variable clinical 
response to the same dose of in-
sulin. Lennon and others ( 1960) 
have demonstrated in vivo that 
such plasma binding is reflected in 
prolonged plasma disappearance of 
}181-labeled insulin. Although al-
tered degradation of insulin by im-
paired renal or hepatic function 
may play an important role, the 
influence of previous insulin ther-
apy appears to be a major factor 
in this altered handling of exog-
enous insulin. This suggests that 
binding of insulin by insulin-neu-
tralizing antibodies may be an im-
portant cause. 
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PROBLEMS IN THE INSULIN DEPENDENT DIABETIC 
Differences in responsiveness of 
muscle and adipose tissue to free 
and complexed insulin may be im-
portant. Plasma-bound insulin may 
be free to act on adipose tissue, 
while only free insulin acts on mus-
cle. Perhaps the insulin !ability 
might result from the gradual satu-
ration of plasma-binding sites with 
complexed insulin free to act only 
on adipose tissue. At a certain level 
of dosage, saturation of the bind-
ing sites occurs, and free insulin is 
then available to act on the mass 
of muscle tissue, thus precipitating 
hypoglycemia. 
Bolinger ( 1964) demonstrated 
markedly delayed disappearance 
times of regular insulin in "brittle" 
diabetics. The characteristics of 
regular insulin in these subjects ap-
proached that of long-acting insulin. 
He postulated that regulatory dif-
ficulties should be exaggerated by 
the use of long-acting insulin, in 
that the slow release rate of insulin 
from injection sites approached the 
rate of degradation, thus permitting 
erratic , filling of the plasma-binding 
sites. He found that in general the 
longer the disappearance time of 
insulin, the greater the proportion 
of regular insulin required for good 
regulation. 
INSULIN RESISTANCE 
Another problem in insulin-
requiring diabetics is the patient 
whose insulin dose increases stead-
ily. Insulin resistance has been arbi-
trarily defined as existing when the 
daily insulin requirement exceeds 
200 units. However, some degree 
of resistance occurs in any individ-
ual requiring over 30 to 40 units 
daily, since this amount provides 
adequate replacement therapy in 
depancreatized human subjects. 
Many factors can increase the re-
quirement for insulin in human dia-
betics and should be considered 
whenever insulin dosage has to be 
raised progressively. Insulin resist-
ance resulting from any of these 
. known factors is usually secondary 
to such factors as obesity, keto~ 
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acidosis, infection, stress, puberty, 
pregnancy, and a number of endo-
crine disturbances, notably thyro-
toxicosis. 
"Primary" or chronic insulin re-
sistance is distinguished by the ab-
sence of any of the factors known 
to aggravate diabetes. In most cases 
it can be attributed to the develop-
ment by the patient of y-globulin 
antibodies to exogenous insulin and 
primarily against the bovine insulin 
component in most commercial 
preparations which are usually mix-
tures of 70% bovine and 30% 
pork insulin (Berson and Yalow, 
1958; Berson et al., 1956; Field et 
al., 1961). 
In some cases of apparently pri-
mary resistance, anti-insulin anti-
bodies cannot be demonstrated, and 
high levels of active plasma insulin 
seem to be physiologically ineffec-
tive (Field, 1960). Tissue unre-
sponsiveness to insulin has been 
postulated to explain such cases. It 
is also theoretically possible that 
primary insulin resistance could re-
sult from excessive amounts of 
binding substances found in associ-
ation with serum albumin or the 
y- or fl-globulins. 
Primary insulin resistance may 
occur in either sex, at any age, and 
in either stable or unstable diabetes 
( Smelo, 1948). Some authors think 
it occurs more commonly where in-
sulin has been given intermittently 
(Calvin and Moloney, 1959). The 
onset is unpredictable and may ter-
minate in a few weeks or persist 
for several years ( Smelo, 1948) . 
This fact makes evaluation of any 
therapeutic program difficult. Sus-
ceptibility to keto-acidosis is about 
the same as before the onset. Con-
trol of the diabetes is usually pos-
sible if enough insulin is given, and 
prognosis is good for ultimate sub-
sidence of the resistance (Smelo, 
1948). 
TREATMENT OF INSULIN 
RESISTA~CE 
I 
The first important measure is to 
give large enough doses of ordinary 
commercial insulin. In most cases 
there is a level which will ulti-
mately overcome the resistance, 
with subsequent improvement in 
insulin sensitivity ( Smelo, 1948). 
Success may depend on willingness 
to administer very large doses of 
insulin, and on the realization that 
subsequent increases in dosage must 
be made by geometric progression. 
With our knowledge of insulin-
neutralizing antibodies, a rational 
treatment can be based on meas-
ures which influence antibody syn-
thesis. Adrenal cortical steroids 
have been used successfully (Field, 
1962; Oakly et al., 1959), al-
though the mechanism of their 
beneficial effect is uncertain. Their 
action may be mediated through an 
effect either on inhibition of ant\-
body synthesis, or by influencing 
the rate of dissociation of the 
antigen-antibody complex. 
Less antigenic types of insulin 
other than commercial beef-pork 
insulin have been used successfully. 
Since the major antigenic property 
of this mixture can be attributed to 
beef insulin, whose molecular struc-
ture differs considerably from hu-
man insulin (Harris et al., 1956; 
Berson and Yalow, 1959), pure 
pork insulin has been used success-
fully in a number of cases (Gold-
man and Kaye, 1962; Feldman et 
al., 1963). The molecular simi-
larity of pork and human insulin 
probably accounts for its weaker 
antigenic properties (Harris et al., 
1956; Berson and Yalow, 1959) . 
The human insulin molecule con-
sists of two long amino acid chains 
designated A and B chains joined 
by disulfide bridges (Harris et al., 
1956) . Pork insulin differs only by 
the terminal amino acid on the 
long B chain. Other more antigenic 
insulins such as beef insulin differ 
by additional changes in the se-
quence of the important amino acid 
triplet at the 8, 9, and 10 positions 
enclosed within the disulfide bridge 
on the shorter A chain. 
Although not generally useful, 
the sulfonylurea drugs have helped 
in a few selected cases of mild insu-
lin resistance. These patients have 
usually been mild, maturity-onset 
diabetics whose insulin doses have 
had to be increased gradually over 
a period of one to two years. Vary-
ing the insulin dose has usually 
made little or no difference in the 
ultimate control of their diabetes. 
Since antibodies against commercial 
insulin of animal origin do not sig-
nificantly neutralize endogenous in-
sulin, stimulation of pancreatic in-
sulin by these agents may bring 
about secretion of enough non-
antigenic endogenous insulin to 
control the diabetes. 
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